The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma
The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.
CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ Melanoma
Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.
Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma
November 23rd 2019Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.
Neoadjuvant T-VEC May Improve Survival in Advanced Melanoma
Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.
Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma
November 23rd 2019Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.
Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma
November 22nd 2019Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.
Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma
November 22nd 2019Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.
Nivolumab/Ipilimumab Misses Coprimary Endpoint in Adjuvant Melanoma Trial
November 20th 2019The combination of nivolumab and ipilimumab did not show a statistically significant improvement in recurrence-free survival compared with single-agent nivolumab as an adjuvant treatment for patients who have had complete surgical removal of stage IIIB/C/D or stage IV melanoma and whose tumors expressed PD-L1
Dr. Daud on Interferon Gamma as a Biomarker in Melanoma
November 8th 2019Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.
Adjuvant Immunotherapy Combinations on Horizon for Melanoma
Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.
European Commission Approves 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma
October 24th 2019The European Commission has approved nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.
Novel Immunotherapy Combos Target GITR to Step on the Gas
October 22nd 2019Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.
Dr. Long on Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets
October 12th 2019Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the long-term data from the phase II ABC study , in which investigators are comparing the efficacy of nivolumab in combination with ipilimumab versus single-agent nivolumab in patients with melanoma brain metastases.